A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173
This study is recruiting at 16 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- AMR Clinical · Tempe, AZ
California · 3
- NewportNativeMD, Inc. · Newport Beach, CA
- California Medical Research Associates · Northridge, CA
- Peninsula Research Associates · Rolling Hills Estates, CA
Colorado · 1
- Asthma & Allergy Associates - Colorado Springs · Colorado Springs, CO
Florida · 4
- AMR Clinical · Doral, FL
- Renstar Medical Research · Ocala, FL
- Avanza Medical Research Center · Pensacola, FL
- USF Health · Tampa, FL
Illinois · 1
- Axis Clinical Trials - Westchester · Westchester, IL
Kentucky · 1
- Allergy & Asthma Specialists, P.S.C. · Owensboro, KY
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
Nevada · 1
- AMR Clinical · Las Vegas, NV
New York · 1
- Equity Medical · New York, NY
Pennsylvania · 2
- Allergy and Clinical Immunology Associates · Pittsburgh, PA
- University of Pittsburgh Medical Center · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.